Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data

BACKGROUND: Little is known on the cost-effectiveness of novel regimens for hepatitis C virus (HCV) compared with standard-of-care with pegylated interferon (pegIFN) and ribavirin (RBV) therapy in developing countries. We evaluated cost-effectiveness of sofosbuvir/ledipasvir for 12 weeks compared wi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Chen, Guo-Feng, Wei, Lai, Chen, Jing, Duan, Zhong-Ping, Dou, Xiao-Guang, Xie, Qing, Zhang, Wen-Hong, Lu, Lun-Gen, Fan, Jian-Gao, Cheng, Jun, Wang, Gui-Qiang, Ren, Hong, Wang, Jiu-Ping, Yang, Xing-Xiang, Jia, Zhan-Sheng, Fu, Qing-Chun, Wang, Xiao-Jin, Shang, Jia, Zhang, Yue-Xin, Han, Ying, Du, Ning, Shao, Qing, Ji, Dong, Li, Fan, Li, Bing, Liu, Jia-Liang, Niu, Xiao-Xia, Wang, Cheng, Wu, Vanessa, Wong, April, Wang, Yu-Dong, Hou, Jin-Lin, Jia, Ji-Dong, Zhuang, Hui, Lau, George
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4898683/
https://ncbi.nlm.nih.gov/pubmed/27276081
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0155934
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars